MedPath

on-randomized confirmatory study of dabigatran bridge therapy in perioperative period of ESD for gastric neoplasms in patients on anticoagulant

Phase 2
Recruiting
Conditions
gastric cancer
Registration Number
JPRN-UMIN000035353
Lead Sponsor
Cancer Institute Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

1 Patients with non-valvular Af in CHADS2 score of 5 or 6 2 Have allergy for dabigatran 3 Have a plan to perform endoscopic resection for esophageal or duodenal lesion simultaneously 4 Had endoscopic treatment within 28 days from registration 5 Have infection requiring systemic treatments 6 Being or possible pregnant 7 Having psychiatric disorder and judged unsuitable for the clinical study. 8 Continuous systemic use of steroid 9 Using itraconazole which is contraindications of combination with dabigatran 10 Unstable angina (newly occurring or a worsening over the 3 weeks prior to ESD) or myocardial infarction within 6 months prior to ESD 11 Severe respiratory disease requiring continuous oxygen supply 12 Uncontrollable hypertension 13 Uncontrollable diabetes mellitus 14 Patients judged unsuitable for clinical study by investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath